Company / Return on Equity (ROE)
GeneDx Holdings Corp. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-6.8%
FY2025
5-year range
-216.4% / -6.8%
FY2021-FY2025
Trend
+68.0%
vs FY2024
Sector context
#101 of 147
Health Care
What the data says
GeneDx Holdings Corp. reports negative total equity of -6.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-6.8% in FY2025 with a 3-year CAGR of +209.6%.
Improved from -77.1% to -6.8% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +209.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#101 of 147 in Health CareTop 69% of 147This company -6.8% Sector average -3.1%
▼
-118.5% below sector average
Key checks
Key Insights
- GeneDx Holdings Corp.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 68.0% year-over-year.
- Currently 3.7pp below the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- Negative profit margin: -17.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -6.8% | +68.0% |
| FY2024 | -21.3% | +72.3% |
| FY2023 | -77.1% | +64.4% |
| FY2022 | -216.4% | -242.2% |
| FY2021 | -63.2% | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026